From: New Voice of Ukraine – Author: Alex Stezhensky
Despite Russia’s full-scale invasion, Ukrainian pharmaceutical companies remain active in developing new drug formulas and securing patents for the production of medicines. Since the start of the war, Darnytsia has registered and launched 44 new medicines on the Ukrainian market.
According to the company, 19 new products were introduced in 2022, followed by 11 in 2023 and another 14 in 2024. For comparison, in the pre-war years of 2020 and 2021, Darnytsia added 10 and 22 new products to its portfolio, respectively.
Over the three years of the war, the company’s product line has reportedly expanded to include treatments for cardiovascular conditions, combat injuries, chronic diseases, and mental health disorders. Darnytsia has developed, tested, and registered both original and generic medicines — including antiepileptic and antihypertensive drugs, anti-inflammatory agents, mucolytics, systemic antimicrobials, painkillers, antidepressants, corticosteroids, as well as medications for allergies and ENT-related conditions.
Voice of Ukraine 